Skip to main content

Advertisement

Table 4 Summary of results from reference and alternative schedules

From: Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives

Schedule Prop OE (of 2746 profiles) (IQR) CV (%) Std dev log(HL) Prop NZ tlag Median (IQR) NZ tlag Prop tail Prop (%) profiles misclassified, with HL cutoff of:
3 h 4 h 5 h 6 h
Ref 0% 0 (0–0) 54.5 0.52 26.5 (n = 729) 6 (6–6.25) 34% (n = 933) 0 0 0 0
A1 49.9% 0.01 (-0.15-0.21) 51.6 0.503 22.1 (n = 606) 6 (6–6.27) 9.36% (n = 257) 7.7 3.9 2.7 2.2
A2 60.2% 0.06 (-0.10-0.29) 51.1 0.482 17.4 (n = 478) 6 (6–6.03) 9.87% (n = 271) 8.6 4.4 3 2.2
A3 59.8% 0.09 (-0.09-0.34) 50.9 0.484 12.5 (n = 344) 12 (12–12) 9.91% (n = 272) 9.5 4.5 3 2.1
A4 66.3% 0.15 (-0.06-0.46) 47.7 0.435 6.96 (n = 191) 12 (12–12) 9.25% (n = 254) 10 4.6 3.4 2.2
  1. For each of the reference and alternative schedules (A1-A4) applied to real patient data: the proportion of profiles that overestimate the HL (relative to the reference HL); median difference in HL (IQR); coefficient of variation of HL (CV) as a percentage; standard deviation of log (HL); the proportion of profiles with a non-zero lag phase (tlag); the median (IQR) tlag for profiles with a non-zero tlag; the proportion of profiles with a tail and the proportions of profiles that are misclassified when the HL estimates are dichotomized using HL cut-offs of three, four, five and six hours. IQR = interquartile range; Ref = reference; OE = overestimation (proportion of HLs from alternative schedule which exceeded reference HL); NZ = non-zero; prop = proportion.